Radiation-activated cytotoxin therapy of neoplastic disease
US6071908A · kind A · utility
0Cited by
0References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 7, 1998 |
| Grant date | Jun 6, 2000 |
| Priority date | — |
| Expiry date | May 7, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D219/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating neoplastic disease wherein a patient in need of such treatment is administered an effective amount of a radiation-activated cytotoxin prodrug (RACP) which has low toxicity, which is reducible by reducing agents generated by the radiolysis of water and which, upon reduction, releases a sufficient amount of a cytotoxic effector of sufficient cytotoxic potency to kill tumor cells. The tumor cells are irradiated with ionizing radiation to reduce the prodrug which is present at the locus of the tumor cells to release the cytotoxic effector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.